Health Care • Biotechnology: Laboratory Analytical Instruments
$181.15 ▼ -0.33
(-0.18%)
MKT CAP: $51.07B • VOL: 1.82M
52W L $108 52W H $183
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$152
MEDIAN
$203
MEAN
$207
HIGH
$246
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE A TAPE
A // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $219.19 | $208.32 | 2025-02-14 | $164.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $228.25 | $213.76 | 2025-02-06 | $170.28 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $206.51 | $199.27 | 2025-01-29 | $173.90 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $184.77 | — | 2025-01-17 | $177.53 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $159.41 | $172.09 | 2025-01-09 | $161.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $215.57 | $188.40 | 2024-12-18 | $157.60 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $175.72 | $182.96 | 2024-12-04 | $168.47 | -4.3% | 48% | C |